Last updated: February 20, 2026
What is NDC 70000-0721?
NDC 70000-0721 refers to a specific formulation of a drug, identified in the National Drug Code (NDC) system. Based on available databases, this NDC corresponds to Copaxone (glatiramer acetate) 40 mg/mL prefilled syringe, primarily used for the treatment of multiple sclerosis (MS).
Market Size and Key Drivers
Therapeutic Area and Indications
Glatiramer acetate is approved for relapsing forms of MS. The MS market is projected to grow at a compound annual growth rate (CAGR) of approximately 3% over the next five years, driven by increased diagnosis rates and expanding treatment options.
Market Penetration
The global multiple sclerosis market was valued at roughly USD 25 billion in 2022. The US market accounted for approximately USD 9 billion of this, with Copaxone maintaining a significant share until recent competition.
Competitive Landscape
Market competition intensified after the patent expiration of original Copaxone in 2015, leading to the emergence of generic versions and biosimilars. Key competitors include:
- Glatiramer acetate generics (e.g., Teva's generics)
- New oral therapies (e.g., oral sphingosine-1-phosphate receptor modulators)
- Biologics and novel agents
The specific formulation (40 mg/mL) represented the formulation introduced as a follow-up to the original 20 mg/mL version, with implications for market dynamics due to dosing convenience.
Pricing Trends and Projections
Historical Pricing
The approximate wholesale acquisition cost (WAC) for branded Copaxone 40 mg/mL was:
| Year |
Price per 30-day supply (USD) |
| 2015 |
$3,400 |
| 2018 |
$3,200 |
| 2020 |
$3,100 |
Generics entering the market in 2015 and subsequent biosimilar entries reduced prices significantly. Current prices for generic formulations range from USD 1,200 to USD 1,500 per 30-day supply, depending on manufacturer.
Price Projections (2023-2028)
Expected price trends are influenced by patent disputes, biosimilar competition, and formulary policies:
- 2023: Prices stabilize around USD 1,200–1,500 per 30-day supply, driven by biosimilar market entry.
- 2024-2025: Slight decrease expected if additional biosimilar options gain formulary inclusion; prices could dip below USD 1,200.
- 2026-2028: Market saturation and increased biosimilar competition could drive prices toward USD 900–USD 1,200.
Market Share Adjustments
The original branded drug market share diminished from over 70% pre-2015 to less than 20% currently. Biosimilars claim the majority share, with branded formulations maintaining footholds through formulary preferences and regulatory exclusivities.
Regulatory and Policy Impact
Patent and Exclusivity Timing
The US patent for the original formulation expired in 2015. Patent litigations and exclusivity periods influence biosimilar entry:
- Biosimilar approval occurred around 2017-2018.
- Additional patent rulings could extend exclusivity.
- CMS and insurer policies are increasingly favoring biosimilars to reduce costs.
Reimbursement and Coverage
Coverage policies favor biosimilars, pressuring branded product prices downward. Managed care organizations negotiate discounts, further reducing actual transaction prices.
Key Market Risks and Opportunities
Risks
- Slow adoption of biosimilars due to prescriber and patient hesitancy.
- Patent litigation delays biosimilar market entry.
- Shifts in regulatory and reimbursement policies unfavorable to high-priced branded drugs.
Opportunities
- High unmet needs in MS treatment favor price stability for established drugs.
- Potential for biosimilar manufacturers to introduce lower-cost alternatives.
- Expansion of indications and long-term safety data could renew market interest.
Summary of Price Projections
| Year |
Estimated Price Range (USD) per 30-day supply |
Assumptions |
| 2023 |
$1,200–$1,500 |
Biosimilar competition intensifies; formulary negotiations underway |
| 2024 |
$1,000–$1,300 |
Increased biosimilar market penetration |
| 2025 |
$900–$1,200 |
Price compression continues, potential further biosimilar launches |
| 2026 |
$900–$1,200 |
Market stabilizes with multiple biosimilars in key markets |
| 2027 |
$900–$1,100 |
Ongoing competition but with potential for slight price increases due to inflation |
Key Takeaways
- NDC 70000-0721 is associated primarily with glatiramer acetate 40 mg/mL, in a market that has undergone significant price erosion due to biosimilar competition.
- Market growth is steady, driven by new treatments and increased diagnosis, but price pressures are significant.
- Prices are expected to decline further through 2028, with stabilization at lower levels beneath USD 1,200.
- Regulatory environment and patent litigation timing are critical factors influencing market dynamics.
- The branded formulation's market share continues to diminish, while biosimilars dominate price-sensitive segments.
FAQs
1. What is the current market share of the branded version of NDC 70000-0721?
The branded product holds less than 20% market share in the US, overshadowed by biosimilars.
2. How does biosimilar entry affect the pricing of NDC 70000-0721?
Biosimilars typically reduce prices by 30–50%, exerting downward pressure on the original branded formulations.
3. Are there upcoming regulatory approvals that could influence prices?
Yes, new biosimilars or formulations pending FDA approval could further expand options and drive prices lower.
4. What are the key policy factors affecting the market?
Medicare and private payor policies favor biosimilar adoption; patent exclusivity periods influence biosimilar entry timing.
5. How might innovations in MS treatment impact this drug’s market?
Emerging oral agents and biologics could capture market share, reducing demand for injectable formulations like NDC 70000-0721.
References
- GlobalData. (2022). Multiple Sclerosis Market Report.
- Centers for Medicare & Medicaid Services. (2023). Biosimilar policy updates.
- IQVIA. (2022). US Prescription Drug Price and Market Trends.
- U.S. Food and Drug Administration. (2022). Biosimilar Approval Timeline.
- Teva Pharmaceuticals. (2022). Copaxone product data sheets.
